Selected research
Industry Research
Regorafenib Drugs Industry Research Report 2026
Market perspective
The global Regorafenib Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Regorafenib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Regorafenib Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Regorafenib Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Regorafenib Drugs include Natco, Bayer, Hansoh Pharma, Kelun Pharmaceutical, Qilu Pharmaceutical, Shanghai Acebright Pharmaceuticals, Yangtze River Pharmaceutical, Zhejiang Huayi Pharmaceutical and Chia Tai Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Regorafenib Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Regorafenib Drugs Market by Company
Natco
Bayer
Hansoh Pharma
Kelun Pharmaceutical
Qilu Pharmaceutical
Shanghai Acebright Pharmaceuticals
Yangtze River Pharmaceutical
Zhejiang Huayi Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Regorafenib Drugs Segment by Type
Original Drug
Generic Drug
Regorafenib Drugs Segment by Application
Metastatic Colorectal Cancer
Gastrointestinal Stromal Tumors
Hepatocellular Carcinoma
Regorafenib Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Regorafenib Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Regorafenib Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Regorafenib Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Regorafenib Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Regorafenib Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Regorafenib Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Original Drug
- Generic Drug
Applications
- Metastatic Colorectal Cancer
- Gastrointestinal Stromal Tumors
- Hepatocellular Carcinoma
Companies covered
- Natco
- Bayer
- Hansoh Pharma
- Kelun Pharmaceutical
- Qilu Pharmaceutical
- Shanghai Acebright Pharmaceuticals
- Yangtze River Pharmaceutical
- Zhejiang Huayi Pharmaceutical
- Chia Tai Tianqing Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Regorafenib Drugs Market Size (2021-2032)
- 2.2.2 Global Regorafenib Drugs Sales (2021-2032)
- 2.2.3 Global Regorafenib Drugs Market Average Price (2021-2032)
- 2.3 Regorafenib Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Original Drug
- 2.3.3 Generic Drug
- 2.4 Regorafenib Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Metastatic Colorectal Cancer
- 2.4.3 Gastrointestinal Stromal Tumors
- 2.4.4 Hepatocellular Carcinoma
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Regorafenib Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Regorafenib Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Regorafenib Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Regorafenib Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Regorafenib Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Regorafenib Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Regorafenib Drugs, Product Type & Application
- 3.8 Global Manufacturers of Regorafenib Drugs, Established Date
- 3.9 Global Regorafenib Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Natco
- 4.1.1 Natco Company Information
- 4.1.2 Natco Business Overview
- 4.1.3 Natco Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Natco Regorafenib Drugs Product Portfolio
- 4.1.5 Natco Recent Developments
- 4.2 Bayer
- 4.2.1 Bayer Company Information
- 4.2.2 Bayer Business Overview
- 4.2.3 Bayer Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Regorafenib Drugs Product Portfolio
- 4.2.5 Bayer Recent Developments
- 4.3 Hansoh Pharma
- 4.3.1 Hansoh Pharma Company Information
- 4.3.2 Hansoh Pharma Business Overview
- 4.3.3 Hansoh Pharma Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hansoh Pharma Regorafenib Drugs Product Portfolio
- 4.3.5 Hansoh Pharma Recent Developments
- 4.4 Kelun Pharmaceutical
- 4.4.1 Kelun Pharmaceutical Company Information
- 4.4.2 Kelun Pharmaceutical Business Overview
- 4.4.3 Kelun Pharmaceutical Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kelun Pharmaceutical Regorafenib Drugs Product Portfolio
- 4.4.5 Kelun Pharmaceutical Recent Developments
- 4.5 Qilu Pharmaceutical
- 4.5.1 Qilu Pharmaceutical Company Information
- 4.5.2 Qilu Pharmaceutical Business Overview
- 4.5.3 Qilu Pharmaceutical Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Qilu Pharmaceutical Regorafenib Drugs Product Portfolio
- 4.5.5 Qilu Pharmaceutical Recent Developments
- 4.6 Shanghai Acebright Pharmaceuticals
- 4.6.1 Shanghai Acebright Pharmaceuticals Company Information
- 4.6.2 Shanghai Acebright Pharmaceuticals Business Overview
- 4.6.3 Shanghai Acebright Pharmaceuticals Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shanghai Acebright Pharmaceuticals Regorafenib Drugs Product Portfolio
- 4.6.5 Shanghai Acebright Pharmaceuticals Recent Developments
- 4.7 Yangtze River Pharmaceutical
- 4.7.1 Yangtze River Pharmaceutical Company Information
- 4.7.2 Yangtze River Pharmaceutical Business Overview
- 4.7.3 Yangtze River Pharmaceutical Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Yangtze River Pharmaceutical Regorafenib Drugs Product Portfolio
- 4.7.5 Yangtze River Pharmaceutical Recent Developments
- 4.8 Zhejiang Huayi Pharmaceutical
- 4.8.1 Zhejiang Huayi Pharmaceutical Company Information
- 4.8.2 Zhejiang Huayi Pharmaceutical Business Overview
- 4.8.3 Zhejiang Huayi Pharmaceutical Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zhejiang Huayi Pharmaceutical Regorafenib Drugs Product Portfolio
- 4.8.5 Zhejiang Huayi Pharmaceutical Recent Developments
- 4.9 Chia Tai Tianqing Pharmaceutical
- 4.9.1 Chia Tai Tianqing Pharmaceutical Company Information
- 4.9.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 4.9.3 Chia Tai Tianqing Pharmaceutical Regorafenib Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Chia Tai Tianqing Pharmaceutical Regorafenib Drugs Product Portfolio
- 4.9.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Regorafenib Drugs Market Scenario by Region
- 5.1 Global Regorafenib Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Regorafenib Drugs Sales by Region: 2021-2032
- 5.2.1 Global Regorafenib Drugs Sales by Region: 2021-2026
- 5.2.2 Global Regorafenib Drugs Sales by Region: 2027-2032
- 5.3 Global Regorafenib Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Regorafenib Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Regorafenib Drugs Revenue by Region: 2027-2032
- 5.4 North America Regorafenib Drugs Market Facts & Figures by Country
- 5.4.1 North America Regorafenib Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Regorafenib Drugs Sales by Country (2021-2032)
- 5.4.3 North America Regorafenib Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Regorafenib Drugs Market Facts & Figures by Country
- 5.5.1 Europe Regorafenib Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Regorafenib Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Regorafenib Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Regorafenib Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Regorafenib Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Regorafenib Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Regorafenib Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Regorafenib Drugs Market Facts & Figures by Country
- 5.7.1 South America Regorafenib Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Regorafenib Drugs Sales by Country (2021-2032)
- 5.7.3 South America Regorafenib Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Regorafenib Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Regorafenib Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Regorafenib Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Regorafenib Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Regorafenib Drugs Sales by Type (2021-2032)
- 6.1.1 Global Regorafenib Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Regorafenib Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Regorafenib Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Regorafenib Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Regorafenib Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Regorafenib Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Regorafenib Drugs Sales by Application (2021-2032)
- 7.1.1 Global Regorafenib Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Regorafenib Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Regorafenib Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Regorafenib Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Regorafenib Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Regorafenib Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Regorafenib Drugs Value Chain Analysis
- 8.1.1 Regorafenib Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Regorafenib Drugs Production Mode & Process
- 8.2 Regorafenib Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Regorafenib Drugs Distributors
- 8.2.3 Regorafenib Drugs Customers
9 Global Regorafenib Drugs Analyzing Market Dynamics
- 9.1 Regorafenib Drugs Industry Trends
- 9.2 Regorafenib Drugs Industry Drivers
- 9.3 Regorafenib Drugs Industry Opportunities and Challenges
- 9.4 Regorafenib Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst